[Federal Register Volume 82, Number 221 (Friday, November 17, 2017)]
[Notices]
[Pages 54386-54387]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-24948]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2014-D-1167]


Controlled Correspondence Related to Generic Drug Development; 
Draft Guidance for Industry; Availability; Correction

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; correction.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration is correcting a notice 
entitled ``Controlled Correspondence Related to Generic Drug 
Development; Draft Guidance for Industry; Availability'' that appeared 
in the

[[Page 54387]]

Federal Register of November 3, 2017. The document announced the 
availability of a draft guidance for industry. The document was 
published with the incorrect docket number. This document corrects that 
error.

FOR FURTHER INFORMATION CONTACT: Lisa Granger, Office of Policy, Food 
and Drug Administration, 10903 New Hampshire Ave. Bldg. 32, Rm. 3330, 
Silver Spring, MD 20993-0002, 301-796-9115, [email protected].

SUPPLEMENTARY INFORMATION: In the Federal Register of Friday, November 
3, 2017 (82 FR 51277), in FR Doc. 2017-23947, the following correction 
is made:
    On page 51277, in the second column, in the header of the document, 
``[Docket FDA-2014-D-1147]'' is corrected to read ``[Docket No. FDA-
2014-D-1167]''.

    Dated: November 9, 2017.
Anna K. Abram,
Deputy Commissioner for Policy, Planning, Legislation, and Analysis.
[FR Doc. 2017-24948 Filed 11-16-17; 8:45 am]
 BILLING CODE 4164-01-P